Cargando…

Evaluating laser photobiomodulation for chemotherapy-induced peripheral neuropathy: a randomised phase II trial

PURPOSE: This study aims to evaluate the efficacy and safety of laser photobiomodulation (PBM) for treatment of established chemotherapy-induced peripheral neuropathy (CIPN) in cancer survivors. METHODS: We conducted a randomised phase II, non-comparative, sham-controlled, single-blinded clinical tr...

Descripción completa

Detalles Bibliográficos
Autores principales: Teng, Christina, Egger, Sam, Blinman, Prunella L., Vardy, Janette L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9758032/
https://www.ncbi.nlm.nih.gov/pubmed/36526802
http://dx.doi.org/10.1007/s00520-022-07463-y
_version_ 1784851953525719040
author Teng, Christina
Egger, Sam
Blinman, Prunella L.
Vardy, Janette L.
author_facet Teng, Christina
Egger, Sam
Blinman, Prunella L.
Vardy, Janette L.
author_sort Teng, Christina
collection PubMed
description PURPOSE: This study aims to evaluate the efficacy and safety of laser photobiomodulation (PBM) for treatment of established chemotherapy-induced peripheral neuropathy (CIPN) in cancer survivors. METHODS: We conducted a randomised phase II, non-comparative, sham-controlled, single-blinded clinical trial in 44 cancer survivors reporting CIPN symptoms at least 3 months following completion of neurotoxic chemotherapy. Participants were randomised 2:1 to either PBM laser or sham control delivered twice weekly for 12 sessions. Assessments were conducted at baseline, the end of intervention (6 weeks), and 6 weeks post intervention (12 weeks). Participants completed neuropathy, quality of life and function questionnaires, and a clinical neurological assessment. The primary outcome was proportion of participants with CIPN response, defined as either symptom resolution or reduction of minimally clinically important difference. RESULTS: In the laser and control groups, CIPN response rates were − 48% and 53% at 6 weeks and 45% and 33% at 12 weeks, respectively. The null hypothesis that the true response rate is 5% in the laser arm was rejected at both 6 and 12 weeks (p < 0.001 for both). Compared to baseline, patient-reported CIPN improved in both laser and control groups after the intervention. At 12 weeks, improvement was sustained in the laser group and approaching baseline in the control group. Clinical signs, quality of life, and function remained stable in both groups. Low-grade “side-effects” were observed in both arms. CONCLUSION: PBM may offer clinically meaningful symptom benefit in cancer survivors with established CIPN with improvement potentially continuing beyond completion of the intervention. A larger study is warranted to evaluate this further.
format Online
Article
Text
id pubmed-9758032
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-97580322022-12-19 Evaluating laser photobiomodulation for chemotherapy-induced peripheral neuropathy: a randomised phase II trial Teng, Christina Egger, Sam Blinman, Prunella L. Vardy, Janette L. Support Care Cancer Research PURPOSE: This study aims to evaluate the efficacy and safety of laser photobiomodulation (PBM) for treatment of established chemotherapy-induced peripheral neuropathy (CIPN) in cancer survivors. METHODS: We conducted a randomised phase II, non-comparative, sham-controlled, single-blinded clinical trial in 44 cancer survivors reporting CIPN symptoms at least 3 months following completion of neurotoxic chemotherapy. Participants were randomised 2:1 to either PBM laser or sham control delivered twice weekly for 12 sessions. Assessments were conducted at baseline, the end of intervention (6 weeks), and 6 weeks post intervention (12 weeks). Participants completed neuropathy, quality of life and function questionnaires, and a clinical neurological assessment. The primary outcome was proportion of participants with CIPN response, defined as either symptom resolution or reduction of minimally clinically important difference. RESULTS: In the laser and control groups, CIPN response rates were − 48% and 53% at 6 weeks and 45% and 33% at 12 weeks, respectively. The null hypothesis that the true response rate is 5% in the laser arm was rejected at both 6 and 12 weeks (p < 0.001 for both). Compared to baseline, patient-reported CIPN improved in both laser and control groups after the intervention. At 12 weeks, improvement was sustained in the laser group and approaching baseline in the control group. Clinical signs, quality of life, and function remained stable in both groups. Low-grade “side-effects” were observed in both arms. CONCLUSION: PBM may offer clinically meaningful symptom benefit in cancer survivors with established CIPN with improvement potentially continuing beyond completion of the intervention. A larger study is warranted to evaluate this further. Springer Berlin Heidelberg 2022-12-17 2023 /pmc/articles/PMC9758032/ /pubmed/36526802 http://dx.doi.org/10.1007/s00520-022-07463-y Text en © The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature 2022, Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.
spellingShingle Research
Teng, Christina
Egger, Sam
Blinman, Prunella L.
Vardy, Janette L.
Evaluating laser photobiomodulation for chemotherapy-induced peripheral neuropathy: a randomised phase II trial
title Evaluating laser photobiomodulation for chemotherapy-induced peripheral neuropathy: a randomised phase II trial
title_full Evaluating laser photobiomodulation for chemotherapy-induced peripheral neuropathy: a randomised phase II trial
title_fullStr Evaluating laser photobiomodulation for chemotherapy-induced peripheral neuropathy: a randomised phase II trial
title_full_unstemmed Evaluating laser photobiomodulation for chemotherapy-induced peripheral neuropathy: a randomised phase II trial
title_short Evaluating laser photobiomodulation for chemotherapy-induced peripheral neuropathy: a randomised phase II trial
title_sort evaluating laser photobiomodulation for chemotherapy-induced peripheral neuropathy: a randomised phase ii trial
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9758032/
https://www.ncbi.nlm.nih.gov/pubmed/36526802
http://dx.doi.org/10.1007/s00520-022-07463-y
work_keys_str_mv AT tengchristina evaluatinglaserphotobiomodulationforchemotherapyinducedperipheralneuropathyarandomisedphaseiitrial
AT eggersam evaluatinglaserphotobiomodulationforchemotherapyinducedperipheralneuropathyarandomisedphaseiitrial
AT blinmanprunellal evaluatinglaserphotobiomodulationforchemotherapyinducedperipheralneuropathyarandomisedphaseiitrial
AT vardyjanettel evaluatinglaserphotobiomodulationforchemotherapyinducedperipheralneuropathyarandomisedphaseiitrial